Chairman of the board
Born 1971. Studied Economics and Law at the School of Business and Economics and at the School of Public Administration, University of Gothenburg.
Board member of Oblique Therapeutics: Chairman of the Board from 2016 -2021 and from 2021 member of the board
Board member: Promore Pharma Ab, S.P. HMSO Göteborg Ab, Inorbit Therapeutics Ab and Deputy Chairman in Alligator Bioscience Ab
Shareholding in Oblique Therapeutics Ab: no shares
Main work experience: Hans-Peter has +20 years of experience in Investment Banking, Private Banking and Asset Management. Hans-Peter has held senior positions at Swedbank Markets, UBS AG, Danske bank and Söderberg & Partners. Hans-Peter has been involved as a board member in Swedish and international companies in Finance and Life Science such as Ancoria Insurance Public Ltd and Irlab Therapeutics Ab
Member of the board
Born 1971. PhD in biomedical research from University of Copenhagen and did his post-doctoral training at Institute Pasteur in Paris. Started as board member of Oblique Therapeutics AB 2023. Chairman of the Board at Atlas Antibodies AB and Atlas Incentives AB.
Main work experience: Søren has more than 20 years of international experience from operational and strategic leadership positions in global pharma and the biotech industry including executive roles at Novo Nordisk, Symphogen and Macrophage Pharma. He has negotiated and operationalized numerous licensing, collaboration and co-development agreements. He is currently the CEO of Alligator Bioscience. Independent in relation to the Company and its management.
Member of the board
Born 1965. B.Sci in chemistry from Stockholm University, a PhD in experimental neurology from Uppsala University and has been a postdoctoral fellow at the University of Southern California (USC), School of Pharmacy. Started as Chairman of Oblique Therapeutics AB 2023. Board member: Board director in Moberg Pharma AB (publ.) and Partner in Ekblom & Denissenko.
Main work experience: Jonas has worked for over 25 years in the Life Science sector. He is an associate professor of pharmacology at Uppsala University. He has trained in strategic planning and business leadership. Previously, he has held management roles in companies in Sweden, Switzerland and USA. Most recently, Jonas was CEO of the Swiss biotechnology company BOWS Pharmaceuticals SA; before that he was active in companies such as Pharmacia, Biovitrum, Sequenom and Invitrogen. He is currently the CEO of Promore Pharma Ab.
